Eichenfield LF, McFalda W, Brabec B, et al. - In 2 identical phase 3 trials (Cantharidin Application in Molluscum Patients [CAMP-1 and CAMP-2]) with a total of 582 candidates, researchers sought to determine the safety and effectiveness of VP-102, a drug-device combination containing cantharidin, 0.7% (w/v), compared with vehicle in people with molluscum contagiosum (MC). Participants in the study were randomized (3:2) to topical application of VP-102 or vehicle to all treatable lesions every 21 days until complete lesion clearance or up to 4 treatments. In achieving complete clearance of MC lesions at the end of the study visit, VP-102 was statistically significantly superior to the vehicle in both trials, with adverse events that were generally mild to moderate and confined to application sites. Such results demonstrate that VP-102 is potentially safe and an effective treatment for MC, a common skin condition with no US Food and Drug Administration–approved treatments.